With the clinical success of lymphoma treatment via combined activations of cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) using anti-CD47 antibody and tumor-targeting Rituximab38, investigations of the therapeutic potential of anti-focal adhesion RNP antibodies against malignancies is scientifically warranted. Here, CD47 is linked to lymphoma.